viewAnavex Life Sciences

Anavex Life shares advance on positive data for ANAVEX 2-73

Shares of Anavex Life Science rise more than 5% after the clinical-stage biopharmaceutical company reported positive data of ANAVEX 2-73 in an exploratory study in a Rett syndrome model

Breakthrough exploratory for Rett Syndrome

Shares of Anavex Life Science (NASDAQ:AVXL) rose more than 5% on Thursday after the clinical-stage biopharmaceutical company reported positive data of ANAVEX 2-73 in an exploratory study in a Rett syndrome model.

Revealed at the 2016 Epilepsy Pipeline Conference being held February 25-26 in San Francisco, the company said chronic oral daily dosing of ANAVEX 2-73 starting at 5.5 weeks of age was conducted in the MECP2 Rett syndrome disease mouse model and continued through a 12-week behavioral testing time point 60 minutes pre‐treatment during the behavioral testing.

Rett syndrome is rare non-inherited genetic postnatal progressive neurodevelopmental disorder that occurs almost exclusively in girls and leads to severe impairments, affecting nearly every aspect of the child’s life: their ability to speak, walk, eat, and even breathe easily.  The hallmark of Rett syndrome is near constant repetitive hand movements while awake.

"The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome," said Steven Kaminsky, PhD, Chief Science Officer of Rettsyndrome.org.

"There is a tremendous need for therapeutic solutions for the individuals living with Rett syndrome and their families, and we are very encouraged by the data we have seen with ANAVEX 2-73," he added.

Anavex Life specialises in therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s Disease, other central nervous system CNS diseases, pain and various types of cancer.

Anavex shares were up 5.7% at $4.48.

Quick facts: Anavex Life Sciences

Price: 4.66 USD

Market: NASDAQ
Market Cap: $280.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Clever Leaves looks to grow its low-cost cannabis business by pursuing a...

Clever Leaves International Inc CEO Kyle Detwiler tells Proactive the privately-held group, which has built an EU-GMP certified cannabis operation in Bogota, Columbia, is aiming to grow the cannabis industry, by being one of the lowest cost manufacturer in the world. Detwiler says the group,...

4 hours, 8 minutes ago

2 min read